Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes BioPharma DiveThe findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) BioPharma Dive The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Lilly debuts more Foundayo data as FDA requests post-marketing trialsNext: FDA moves toward easing restrictions on certain peptides Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026